Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 6, 1999, Pages 661-671

  Michelet, Christian ^{a,b,c,d,e,f,g}   Bellissant, Eric ^a,b,c,d,e,f   Ruffault, Annick ^a,b,c,d,e,f   Arvieux, Cedric ^a,b,c,d,e,f   Delfraissy, Jean François ^a,b,c,d,e,f   Raffi, François ^a,b,c,d,e,f   Bazin, Claude ^a,b,c,d,e,f   Renard, Isabelle ^a,b,c,d,e,f   Sébille, Véronique ^a,b,c,d,e,f   Chauvin, Jean Pierre ^a,b,c,d,e,f   Dohin, Elisabeth ^a,b,c,d,e,f   Cartier, François ^a,b,c,d,e,f  

^a Lab de Bacteriologie Virologie   (France)

^b BICÊTRE HOSPITAL   (France)

^c Ctrs Hosp Universitaires d'Angers   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e Abbott   (France)

^f Laboratoire Roche   (France)

^g PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANCE; NAUSEA; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PILOT PROJECTS; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 0032978157     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)90088-7     Document Type: Article

References (26)

1. 1. Carpenter CC, Fischl MA, Hammer SM, Hirsh MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280:78-86.
2. 2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. 4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. 4. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-9.
5. 5. Gulick RM, Mellors JW, Havlir D, Eron J, Gonzales C, McMahon D, et al. Indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC): concurrent or sequential therapy in ZDV-experienced patients (abstract 189). In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington (DC): American Society for Microbiology; 1997. p. 259.
6. 6. Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-6.
7. 7. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-6.
8. 8. Schmit JC, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995-9.
9. 9. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
10. 10. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-66.
11. 11. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
12. 12. Merry C, Barry MG, Mulcahy F, Heavey J, Tjia J, Gibbons F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-33.
13. 13. Schapiro JM, Winters MA, Stewart F, Stewart F, Efron B, Norris J, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
14. 14. Hsu A, Granneman GR, Cao G, Carothers L, El-Shourbagy T, Baroldi P, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-64.
15. 15. Cameron W, Sun E, Markowitz M, et al. Combination use of ritonavir and saquinavir in HIV infected patients: preliminary safety and activity data (abstract ThB 934). In: Program and abstracts of the XI International Conference on AIDS (Vancouver, Canada). Vancouver: XI International Conference on AIDS Society; 1996: suppl 20.
16. 16. Kempf DJ, Marsh KC, Paul DA, Knigge MF, Norbeck UW, Kohlbrenner WE, et al. Antiviral and pharmacokinetic properties of C2-symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1991;35:2209-14.
17. 17. Eberle J, Bechowsky B, Rose D, Hauser U, Von der Helm K, Gûrtler L, et al. Resistance of HIV type 1 to proteinase inhibitor RO 31-8959. AIDS Res Hum Retroviruses 1995; 11:671-6.
18. 18. Carr A, Emery S, Kelleher A, Law M, Cooper DA. CD8+ lymphocyte response to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr 1996;13:320-6.
19. 19. Autran B, Carcelain T, Li S, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
20. 20. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
21. 3: 60-week follow up (abstract 383). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria (VA): Infectious Disease Society of America; 1998. p. 150.
22. 22. Clumeck N, Colebunders B, Vandercam B, Vandercam B, Kabeya K, Cassano P, et al. Randomized comparative outcome trial of indinavir and ritonavir in protease inhibitors naive HIV patients with CD4 below 100 cells/μL (abstract 386). In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria (VA): Infectious Disease Society of America; 1998. p. 151.
23. 23. Cornelissen M, Van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J. Pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997;71:6348-58.
24. 24. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owwen S, Andreoni M, et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996;173:1379-87.
25. 25. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Ryschmann OT, von Overbeck J, et al. Toxicity, efficacy, plasma advanced HIV infection treated with ritonavir plus saquinavir: Swiss HIV Cohort Study. AIDS 1997;11: F95-9.
26. 26. Kaufmann, GR, Duncombe C, Cunningham P, Beveridge A, Carr A, Sayer D, et al. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1 infected individuals. AIDS 1998;12:1625-30.